Last reviewed · How we verify
Lesion count
Lesion count drug works by counting and tracking lesions in the body.
Lesion count drug works by counting and tracking lesions in the body. Used for Tracking and monitoring lesions in various dermatological conditions.
At a glance
| Generic name | Lesion count |
|---|---|
| Also known as | AK lesion recurrence |
| Sponsor | Peplin |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
This drug uses advanced imaging technology to identify and quantify lesions, providing valuable information for diagnosis and treatment planning.
Approved indications
- Tracking and monitoring lesions in various dermatological conditions
Common side effects
- Unknown
Key clinical trials
- Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma (NA)
- One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors (PHASE1, PHASE2)
- Longitudinal Assessment of Iron Rims in MS Lesions
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- CBF and NCF Changes With Brain Radiation
- Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease (PHASE2)
- PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases (PHASE1)
- Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lesion count CI brief — competitive landscape report
- Lesion count updates RSS · CI watch RSS
- Peplin portfolio CI